Cannabinoid Clinical Trials: Teen Cannabis Intervention Study
Adolescent cannabis use disorder intervention is critical due to neurodevelopmental risks during brain maturation. Clinical trials provide essential data on effective teen cannabis use disorder treatments. Evidence-based interventions remain limited but…
Trump Plans Psychedelic Executive Order (Newsletter: April 17, 2026)
The 2026 psychedelic drug policy developments could reshape access to psilocybin and MDMA treatments currently in FDA trials. These changes matter clinically for patients with PTSD and depression. Clinicians should monitor these developments closely for…
IGC Pharma Nears Completion of Phase 2 CALMA Trial Enrollment
The phase 2 CALMA trial enrollment by IGC Pharma has reached 80%, marking significant progress in cannabis-derived therapeutic research. This trial aims to establish safety and efficacy data for a novel cannabis pharmaceutical candidate. Clinicians…
An Investigation of Cannabis and Mood Study for Class Project ($25 RAFFLE FOR …)
Student-led cannabis research projects often lack proper clinical research standards, impacting data validity. This mood study highlights challenges in informal cannabis research. Clinicians should be aware of these issues when discussing cannabis…
Medical Cannabis Market Growth and Clinical Research Outlook 2026-2033
The medical cannabis market growth 2026 is driven by intensified clinical research and development of pharmaceutical-grade products. Clinicians must stay informed about emerging evidence to guide patient care. This evolving landscape promises more…
Proposed Rule Would Allow Expansion of Cannabis Research in Missouri
Missouri cannabis research expansion is proposed to enable new research facilities focused on cannabis clinical studies. This rule aims to remove restrictions limiting research infrastructure and accelerate evidence development. Clinicians could benefit…
France Extends Experimental Medical Cannabis Access Until 2027
France medical cannabis access extension has been announced, allowing experimental use until 2027. This development is important for cannabis medicine and clinical practice. Clinicians should monitor emerging evidence related to this extension.
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav
Jazz Pharmaceuticals is advancing pharmaceutical grade CBD research with new findings on Epidiolex and Xywav. This research helps establish evidence-based dosing protocols and safety profiles. Such data is critical for broader cannabinoid medicine…
Hawaii Lawmakers Approve Bill To Create Psychedelics Task Force
Hawaii lawmakers have approved a bill to create a psychedelics task force study focused on psilocybin and MDMA. This task force will examine therapeutic applications and regulatory considerations. The study reflects growing interest in psychedelic…
Marijuana Rescheduling Countdown: Why the “Order of Operations” and Todd Blanche’s Role Matter
The marijuana rescheduling countdown highlights critical regulatory changes that could accelerate clinical trial timelines. This shift aims to remove barriers delaying Phase II and III studies, enabling better evidence-based cannabis therapies.…
